# EDGAR Filing Document

**Accession Number:** 0001619841
**File Stem:** 0001104659-23-026032
**Filing Date:** 2023-2
**Character Count:** 11904
**Document Hash:** d5cbe60eed82aa1948c8736dc1ba21f3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-026032.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001104659-23-026032

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230223

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** RA Capital Healthcare Fund LP
- **CENTRAL INDEX KEY:** 0001315082
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39247
- **FILM NUMBER:** 23675473

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET
- **STREET 2:** 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6177782500

**MAIL ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET
- **STREET 2:** 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER NAME:**
- **FORMER CONFORMED NAME:** RA Capital Biotech Fund LP
- **DATE OF NAME CHANGE:** 20050121
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** RA CAPITAL MANAGEMENT, L.P.
- **CENTRAL INDEX KEY:** 0001346824
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39247
- **FILM NUMBER:** 23675474

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET, 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-778-2500

**MAIL ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET, 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER NAME:**
- **FORMER CONFORMED NAME:** RA CAPITAL MANAGEMENT, LLC
- **DATE OF NAME CHANGE:** 20051213
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kolchinsky Peter
- **CENTRAL INDEX KEY:** 0001384859

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39247
- **FILM NUMBER:** 23675472

**MAIL ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET
- **STREET 2:** 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shah Rajeev M.
- **CENTRAL INDEX KEY:** 0001619841

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39247
- **FILM NUMBER:** 23675471

**MAIL ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET
- **STREET 2:** 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enliven Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001672619
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6200 LOOKOUT ROAD
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** 720-647-8519

**MAIL ADDRESS:**
- **STREET 1:** 6200 LOOKOUT ROAD
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMARA Inc.
- **DATE OF NAME CHANGE:** 20160419

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>RA CAPITAL MANAGEMENT, L.P.<br><sub>(Last) (First) (Middle)</sub><br>200 BERKELEY STREET, 18TH FLOOR<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Enliven Therapeutics, Inc. [ ELVN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>RA Capital Healthcare Fund LP<br><sub>(Last) (First) (Middle)</sub><br>200 BERKELEY STREET<br>18TH FLOOR<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Enliven Therapeutics, Inc. [ ELVN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kolchinsky Peter<br><sub>(Last) (First) (Middle)</sub><br>C/O RA CAPITAL MANAGEMENT<br>200 BERKELEY STREET, 18TH FLOOR<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Enliven Therapeutics, Inc. [ ELVN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shah Rajeev M.<br><sub>(Last) (First) (Middle)</sub><br>C/O RA CAPITAL MANAGEMENT<br>200 BERKELEY STREET, 18TH FLOOR<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-23 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Enliven Therapeutics, Inc. [ ELVN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-23 |  | A |  | 1152460 | A | <sup>(1)</sup> | 2122465<sup>(2)(3)</sup> | I | See Footnotes<sup>(3)(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Received in exchange for 3,905,254 shares of common stock of Enliven Therapeutics, Inc. ("Enliven") pursuant to an Agreement and Plan of Merger by and among Enliven, the Issuer, and Iguana Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on February 23, 2023, Merger Sub merged with and into Enliven (the "Merger"), with Enliven surviving the Merger as a wholly-owned subsidiary of the Issuer and the surviving corporation of the Merger. Upon the closing of the Merger, each share of Enliven common stock was converted into the right to receive 0.295105222522519 shares of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Imara, Inc. to Enliven Therapeutics, Inc.

(2) On February 23, 2023, the Issuer effected a 1-for-4 reverse stock split of its common stock (the "Reverse Stock Split"). The number of shares reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

(3) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

(4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

**Signature:** /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.  
**Date:** 2023-02-27

**Signature:** /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.  
**Date:** 2023-02-27

**Signature:** /s/ Peter Kolchinsky, individually  
**Date:** 2023-02-27

**Signature:** /s/ Rajeev Shah, individually  
**Date:** 2023-02-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**